# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-26-001968
**Filing Date:** 2026-1
**Character Count:** 8368
**Document Hash:** e5d57844255b92190cf10cc664df4799
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-001968.hdr.sgml**: 20260107

**ACCESSION NUMBER**: 0001213900-26-001968

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260107

**FILED AS OF DATE**: 20260107

**DATE AS OF CHANGE**: 20260107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 26514001

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 07, 2026**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Change of Director's Interest Notice - D Stamler](ea027209201ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Julian Babarczy |
|  | Julian Babarczy |
|  | Chairman |

---

Date: January 07, 2026

## Exhibit 99.1

**Exhibit 99.1**

---

| |
|:---|
| **Appendix 3Y** |
| **Change of Director** **'s Interest Notice** |

---

*Rule 3.19A.2*

 

**Appendix 3Y**

**Change of Director's Interest Notice**

*Information or documents not available now must be given to ASX* as *soon* as *available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

---

| | |
|:---|:---|
| **Name of entity** | Alterity Therapeutics Limited |
| **ABN** | 37 080 699 065 |

---

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

---

| | |
|:---|:---|
| **Name of director** | David Stamler |
| **Date of last notice** | 21 November 2025 |

---

**Part 1 - Change of director's relevant interests in securities**

 

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| **Direct or indirect interest** | Direct and Indirect |
| **Nature of indirect interest** | HSBC CUSTODY NOMINEES (AUSTRALIA) |
| **(including registered holder)** | LIMITED - 133,333 - AMERICAN DEPOSITARY SHARES |
|  | (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) |
| **Date of change** | (1) N/A |
|  | (2) N/A |
|  | (3) N/A |
|  | (4) N/A |
|  | (5) 06 January 2026 |
|  | (6) N/A |
|  | (7) N/A |
| **No. of securities held prior to change** | (1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT |
|  | (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT |
|  | (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT |
|  | (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT |
|  | (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT |
|  | (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT |
|  | (7) 133,333 - AMERICAN DEPOSITARY SHARES |
|  | (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT |

---

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

---

| |
|:---|
| **Appendix 3Y** |
| **Change of Director** **'s Interest Notice** |

---

---

| | |
|:---|:---|
| **Class** | (1) FULLY PAID ORDINARY SHARES<br> (2) LISTED OPT EXP 31/08/2026 @ $0.01<br> (3) LISTED OPT EXP 26/02/2027 @ $0.028<br> (4) UNLISTED OPT EXP 21/03/2029 @ US$0.0030<br> (5) UNLISTED OPT EXP 06/01/2026 @ $0.0320<br> (6) UNLISTED OPT EXP 08/08/2030 @ US$0.0086<br> (7) AMERICAN DEPOSITARY SHARES |
| **Number acquired** | (1) NIL<br> (2) NIL<br> (3) NIL<br> (4) NIL<br> (5) NIL<br> (6) NIL<br> (7) NIL |
| **Number disposed** | (1) NIL<br> (2) NIL<br> (3) NIL<br> (4) NIL<br> (5) 91,392,720 - UNLISTED OPT EXP 06/01/2026 @ $0.0320<br> (6) NIL<br> (7) NIL |
| **Value/Consideration** | (1) N/A<br> (2) N/A<br> (3) N/A<br> (4) N/A<br> (5) NIL<br> (6) N/A<br> (7) N/A |
| **No. of securities held after change** | (1) 11,688,312 - FULLY PAID ORDINARY SHARES - DIRECT<br> (2) 2,380,952 - LISTED OPT EXP 31/08/2026 @ $0.01 - DIRECT<br> (3) 1,515,152 - LISTED OPT EXP 26/02/2027 @ $0.028 - DIRECT<br> (4) 40,000,200 - UNLISTED OPT EXP 21/03/2029 @ US$0.0030 - DIRECT<br> (5) NIL - UNLISTED OPT EXP 06/01/2026 @ $0.0320 - DIRECT<br> (6) 290,400,000 - UNLISTED OPT EXP 08/08/2030 @ US$0.0086 - DIRECT<br> (7) 133,333 - AMERICAN DEPOSITARY SHARES<br> (equivalent to 79,999,800 FULLY PAID ORDINARY SHARES) - INDIRECT |
| **Nature of change** | (1) N/A<br> (2) N/A<br> (3) N/A<br> (4) N/A<br> (5) Options expired<br> (6) N/A<br> (7) N/A |

---

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 2

---

| |
|:---|
| **Appendix 3Y** |
| **Change of Director** **'s Interest Notice** |

---

**Part 2 - Change of director's relevant interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

---

| | |
|:---|:---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder (if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change** | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration** | N/A |
| **Interest after change** | N/A |

---

**Part 3 - <sup>+</sup>Closed period**

---

| | |
|:---|:---|
| **Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?** | N/A |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3